Annual EBITDA
-$261.52 M
-$102.47 M-64.43%
December 31, 2024
Summary
- As of March 12, 2025, PHAT annual EBITDA is -$261.52 million, with the most recent change of -$102.47 million (-64.43%) on December 31, 2024.
- During the last 3 years, PHAT annual EBITDA has fallen by -$124.95 million (-91.49%).
- PHAT annual EBITDA is now -20411.53% below its all-time high of -$1.27 million, reached on December 31, 2018.
Performance
PHAT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$55.66 M
+$11.24 M+16.80%
December 31, 2024
Summary
- As of March 12, 2025, PHAT quarterly EBITDA is -$55.66 million, with the most recent change of +$11.24 million (+16.80%) on December 31, 2024.
- Over the past year, PHAT quarterly EBITDA has stayed the same.
- PHAT quarterly EBITDA is now -19363.29% below its all-time high of -$286.00 thousand, reached on September 30, 2018.
Performance
PHAT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$261.52 M
+$10.69 M+3.93%
December 31, 2024
Summary
- As of March 12, 2025, PHAT TTM EBITDA is -$261.52 million, with the most recent change of +$10.69 million (+3.93%) on December 31, 2024.
- Over the past year, PHAT TTM EBITDA has stayed the same.
- PHAT TTM EBITDA is now -91341.26% below its all-time high of -$286.00 thousand, reached on September 30, 2018.
Performance
PHAT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PHAT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -64.4% | 0.0% | 0.0% |
| 3 y3 years | -91.5% | -22.9% | -54.0% |
| 5 y5 years | -4.2% | -22.9% | -54.0% |
PHAT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -91.5% | at low | -95.7% | +24.3% | -91.5% | +3.9% |
| 5 y | 5-year | -110.6% | at low | -187.7% | +42.6% | -110.6% | +3.9% |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +42.6% | <-9999.0% | +3.9% |
Phathom Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$261.52 M(+64.4%) | -$55.66 M(-16.8%) | -$261.52 M(-3.9%) |
| Sep 2024 | - | -$66.90 M(-9.0%) | -$272.21 M(+14.2%) |
| Jun 2024 | - | -$73.48 M(+12.2%) | -$238.33 M(+21.6%) |
| Mar 2024 | - | -$65.47 M(-1.3%) | -$196.07 M(+23.3%) |
| Dec 2023 | -$159.05 M(-6.3%) | -$66.36 M(+101.0%) | -$159.05 M(+15.3%) |
| Sep 2023 | - | -$33.02 M(+5.7%) | -$137.97 M(-5.9%) |
| Jun 2023 | - | -$31.23 M(+9.8%) | -$146.59 M(-8.6%) |
| Mar 2023 | - | -$28.45 M(-37.2%) | -$160.47 M(-5.5%) |
| Dec 2022 | -$169.80 M(+24.3%) | -$45.28 M(+8.7%) | -$169.80 M(+7.9%) |
| Sep 2022 | - | -$41.64 M(-7.7%) | -$157.44 M(+4.4%) |
| Jun 2022 | - | -$45.10 M(+19.4%) | -$150.84 M(+7.1%) |
| Mar 2022 | - | -$37.78 M(+14.8%) | -$140.91 M(+3.2%) |
| Dec 2021 | -$136.57 M | -$32.92 M(-6.1%) | -$136.57 M(-12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$35.05 M(-0.3%) | -$155.98 M(+1.5%) |
| Jun 2021 | - | -$35.16 M(+5.1%) | -$153.66 M(+11.1%) |
| Mar 2021 | - | -$33.45 M(-36.1%) | -$138.26 M(+11.4%) |
| Dec 2020 | -$124.16 M(-50.5%) | -$52.32 M(+59.8%) | -$124.16 M(-26.4%) |
| Sep 2020 | - | -$32.73 M(+65.6%) | -$168.81 M(-16.5%) |
| Jun 2020 | - | -$19.76 M(+2.1%) | -$202.19 M(-24.9%) |
| Mar 2020 | - | -$19.35 M(-80.0%) | -$269.06 M(+7.2%) |
| Dec 2019 | -$250.95 M(>+9900.0%) | -$96.96 M(+46.6%) | -$250.95 M(+62.5%) |
| Sep 2019 | - | -$66.12 M(-23.7%) | -$154.46 M(+74.3%) |
| Jun 2019 | - | -$86.63 M(+6885.9%) | -$88.63 M(+4320.4%) |
| Mar 2019 | - | -$1.24 M(+158.9%) | -$2.00 M(+162.1%) |
| Dec 2018 | -$1.27 M | -$479.00 K(+67.5%) | -$765.00 K(+167.5%) |
| Sep 2018 | - | -$286.00 K | -$286.00 K |
FAQ
- What is Phathom Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals annual EBITDA year-on-year change?
- What is Phathom Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Phathom Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals TTM EBITDA year-on-year change?
What is Phathom Pharmaceuticals annual EBITDA?
The current annual EBITDA of PHAT is -$261.52 M
What is the all time high annual EBITDA for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high annual EBITDA is -$1.27 M
What is Phathom Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, PHAT annual EBITDA has changed by -$102.47 M (-64.43%)
What is Phathom Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of PHAT is -$55.66 M
What is the all time high quarterly EBITDA for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high quarterly EBITDA is -$286.00 K
What is Phathom Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, PHAT quarterly EBITDA has changed by $0.00 (0.00%)
What is Phathom Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of PHAT is -$261.52 M
What is the all time high TTM EBITDA for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high TTM EBITDA is -$286.00 K
What is Phathom Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, PHAT TTM EBITDA has changed by $0.00 (0.00%)